Search Results for "covid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for covid. Results 1 to 10 of 93 total matches.
COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis ...
The FDA has issued an Emergency Use Authorization
(EUA) for the long-acting investigational IV
monoclonal antibody pemivibart (Pemgarda –
Invivyd) for pre-exposure prophylaxis of COVID-19
in persons ≥12 years old (weight ≥40 kg) who have
moderate to severe immune compromise and
are unlikely to respond adequately to COVID-19
vaccination (see Table 1). Pemgarda is the only drug
that is currently authorized in the US for pre-exposure
prophylaxis of COVID-19. Tixagevimab/cilgavimab
(Evusheld) was previously available under an EUA for
this indication, but it lacks activity against...
Med Lett Drugs Ther. 2024 May 13;66(1702):79-80 doi:10.58347/tml.2024.1702e | Show Introduction Hide Introduction
Rozanolixizumab (Rystiggo) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
infections, including COVID-19 pneumonia; patients
with an active infection should not receive the drug ...
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal
Fc receptor (FcRn) blocker, has been approved by the
FDA for treatment of generalized myasthenia gravis in
adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
It is the first drug to be approved for treatment of
generalized myasthenia gravis in patients with anti-MuSK antibodies. Four other biologic drugs – the
FcRn blocker efgartigimod alfa (Vyvgart; Vyvgart
Hytrulo) and the complement inhibitors eculizumab
(Soliris), ravulizumab (Ultomiris), and zilucoplan
(Zilbrysq) – are...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):29-31 doi:10.58347/tml.2024.1696c | Show Introduction Hide Introduction
Etrasimod (Velsipity) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
receptor modulators could increase the risk of COVID-19 or its immunological complications is unclear ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be approved
in the US for this indication; ozanimod (Zeposia) was
the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9 doi:10.58347/tml.2023.1690b | Show Introduction Hide Introduction
COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024 ...
A new 2023-2024 formulation of the adjuvanted
protein subunit COVID-19 vaccine manufactured by
Novavax that was developed to more closely target
currently circulating SARS-CoV-2 variants has been
made available in the US under an FDA Emergency Use Authorization (EUA) for use in persons ≥12
years old. The original formulation of the Novavax
vaccine is no longer authorized for use in the US.
In September, updated formulations of the mRNA
COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were
licensed by the FDA for use in persons ≥12 years old
and...
Med Lett Drugs Ther. 2023 Nov 13;65(1689):182-3 doi:10.58347/tml.2023.1689b | Show Introduction Hide Introduction
Correction
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
Correction
In our article in issue 1687 on the updated 2023-2024 COVID-19
vaccines from Pfizer ...
In our article in issue 1687 on the updated 2023-2024 COVID-19 vaccines
from Pfizer and Moderna (Med Lett Drugs Ther 2023; 65:161),
the doses and formulations of the Pfizer vaccine were incorrect. A
revised table has been posted in the online version of the article.
Med Lett Drugs Ther. 2023 Nov 13;65(1689):184 doi:10.58347/tml.2023.1689d | Show Introduction Hide Introduction
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2023-2024
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2023-2024 ...
New 2023-2024 formulations of the mRNA COVID-19
vaccines manufactured by Pfizer/BioNTech
(Comirnaty) and that more
closely target currently circulating variants have
been licensed by the FDA for use in persons ≥12 years
old and made available under FDA Emergency Use
Authorizations (EUAs) for use in persons 6 months
to 11 years old. The bivalent (original and Omicron
BA.4/5) formulations of the Pfizer and Moderna
vaccines are no longer authorized for use in the US.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):167-8 doi:10.58347/tml.2023.1687c | Show Introduction Hide Introduction
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
be considered.
Vaccination of persons with moderate or severe
COVID-19 should be postponed until after ...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):161-6 doi:10.58347/tml.2023.1687a | Show Introduction Hide Introduction
Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines (online only) ...
View the Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e1 doi:10.58347/tml.2023.1687e | Show Introduction Hide Introduction
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
between October and April, peaking in December or
January. The COVID-19 pandemic disrupted RSV ...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6 doi:10.58347/tml.2023.1686a | Show Introduction Hide Introduction
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
after a
pause for the COVID-19 pandemic; the results for all
participants (n=3012) were consistent ...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7 doi:10.58347/tml.2023.1685a | Show Introduction Hide Introduction